|
業務類別
|
Biotechnology |
|
業務概覽
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
| 公司地址
| 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 704-4660 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.vikingtherapeutics.com |
| 員工數量
| 53 |
| Mr. Greg S. Zante |
Chief Financial Officer and Principal Accounting Officer |
美元 475.00K |
11/02/2026 |
| Dr. Brian Lian, PhD |
President, Chief Executive Officer and Director |
美元 640.00K |
11/02/2026 |
| Ms. Marianne Mancini |
Chief Operating Officer |
美元 490.00K |
11/02/2026 |
|
|
| Mr. Charles A. Rowland, Jr,M.B.A. |
Independent Director |
08/04/2025 |
| Mr. J. Matthew Singleton |
Independent Director |
11/02/2026 |
| Mr. Matthew W. Foehr |
Independent Director |
11/02/2026 |
| Dr. Brian Lian, PhD |
President, Chief Executive Officer and Director |
11/02/2026 |
| Dr. Lawson Macartney, D.V.M.,PhD |
Chairperson of the Board |
11/02/2026 |
| Dr. S. Kathryn Rouan, PhD |
Independent Director |
08/04/2025 |
|
|
|
|
